Medication Management for ACE Inhibitor Initiation in Heart Failure with Hypotension

Rationale for Not Reducing Current Medications

The European Society of Cardiology recommends starting ACE inhibitors at a low dose (2.5 mg lisinopril or equivalent) without reducing any current medications, as the cardiorenal protection benefits outweigh the risk of asymptomatic hypotension in patients with heart failure 1, 2, 3.
Beta-blockers, such as metoprolol, should never be reduced or stopped suddenly due to the risk of rebound myocardial ischemia/infarction and arrhythmias, and the target dose for heart failure is 200 mg daily 1, 2, 4.
Spironolactone provides significant mortality benefit in heart failure, preventing 57 deaths per 1000 patient-years, and should not be reduced below 25 mg daily 3, 5.
Loop diuretics, such as torsemide, are essential for managing congestion, and reducing them would risk fluid retention, which is more dangerous than asymptomatic hypotension 1, 2, 4.

The American Heart Association recommends starting with lisinopril 2.5 mg once daily, which provides cardiorenal protection while minimizing hypotension risk 5, 3.
ACE inhibitors reduce mortality by 13 deaths per 1000 patient-years in heart failure 3.

The European Society of Cardiology guidelines state that asymptomatic hypotension does not usually require any change in therapy, but symptomatic hypotension requires medication adjustment 1, 2, 4.
The first step in managing symptomatic hypotension is to reconsider the need for any vasodilators, such as nitrates or calcium channel blockers 1, 2, 4.
The second step is to consider reducing diuretic dose temporarily if there are no signs of congestion 1, 2, 4.
The third step is to halve the beta-blocker dose if symptomatic hypotension persists 1, 2, 4.

The American College of Cardiology recommends checking blood pressure, renal function, and potassium within 1-2 weeks after ACE inhibitor initiation, and repeating monitoring 1-2 weeks after each dose increase 5, 3.
More frequent monitoring is needed if spironolactone is co-administered due to the risk of hyperkalemia 5, 6.

The European Society of Cardiology recommends gradually up-titrating ACE inhibitors every 2 weeks as tolerated, with a target dose of lisinopril 10-20 mg daily 1, 3.
A modest fall in glomerular filtration rate (GFR) at ACE inhibitor initiation is expected and correlates with better long-term renal protection 5, 3.
Creatinine increases up to 30% above baseline are acceptable unless accompanied by hyperkalemia >5.5 mEq/L 5, 3.